Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09BDE
|
|||
| Former ID |
DIB008077
|
|||
| Drug Name |
PAC-14028
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [1] | |
| Company |
Pacific Pharmaceuticals Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22F5N3O3S
|
|||
| Canonical SMILES |
CCCC1=C(C=CC(=N1)C(F)(F)F)C=CC(=O)NC(C)C2=CC(=C(C(=C2)F)NS(=O)(=O)C)F
|
|||
| InChI |
1S/C21H22F5N3O3S/c1-4-5-17-13(6-8-18(28-17)21(24,25)26)7-9-19(30)27-12(2)14-10-15(22)20(16(23)11-14)29-33(3,31)32/h6-12,29H,4-5H2,1-3H3,(H,27,30)/b9-7+/t12-/m1/s1
|
|||
| InChIKey |
UKGJZDSUJSPAJL-YPUOHESYSA-N
|
|||
| CAS Number |
CAS 1005168-10-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02052531) Efficacy and Safety Study of PAC-14028 Cream in Dermal Pruritus. U.S. National Institutes of Health. | |||
| REF 2 | Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.